EU GDP definition

EU GDP means the European Union Good Distribution Practices. “EU GMP” means the European Union Good Manufacturing Practices.
Sample 1Sample 2Sample 3
EU GDP means European Union good distribution practice; "EU-GMP" means European Union good manufacturing practice; "Eurasia Infused" means Eurasia Infused Cosmetics Inc.; "EuroLife" means EuroLife Brands Inc.;
Sample 1

Examples of EU GDP in a sentence

  • The following table, compiled using Eurostat data120 concerning final consumption expenditure of households provides an overview of the size of the EU-wide consumption for non-food products in relation to the whole EU GDP.

  • Between 2007 and 2010, the EU GDP remained relatively stable in nominal terms at circa 12,000 billion EUR.

  • VAT raised slightly more than EUR 1 trillion in 2015, which corresponds to 7% of EU GDP or 17.6% of total national tax revenues1.

  • A recent study has estimated that IPR-intensive sectors account for around 39% of EU GDP (worth some EUR 4.7 trillion annually) and, taking indirect jobs into account, up to 35% of all jobs1.

  • There are clear net long term economic benefits of an annual increase in the EU GDP in the range of 0.3%-2%.

  • Each year, the consumption of non-food products accounted for roughly 900 billion EUR, which represents 13% of the total household consumption or about 7.5% of the total EU GDP.

  • The underinvestment in business R&D is one of the reasons behind the widening of the EU’s productivity gap compared to the US.The R&D investment gap to reach the 3% EU GDP amounted to EUR 144 billion for the year 201626.

  • Investment rates in 2016 represented 1.8% of EU GDP, down from 2.2% in 200910.

  • Over the same period, IPR- intensive industries accounted for around 45% of the EU GDP, worth some € 6.6 trillion annually.

  • A quarter of EU GDP growth and 40% of productivity growth are due to ICT19.

Related to EU GDP

  • EU GDPR means Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC.

  • EUA or “Extended Use Agreement” means, with respect to the HC Program, an agreement which sets forth the set-aside requirements and other Development requirements under the HC Program.

  • GDP or “Gross Domestic Product” for the purposes of this LOA means the expenditure side value of all goods and services produced in British Columbia for a given year as stated in the BC Economic Accounts;

  • EUWA means the European Union (Withdrawal) Act 2018, as amended.

  • GDPR means the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation).

  • Major EU Country Major EU Country means France, Germany, Italy, Spain or the United Kingdom.

  • Clinical evaluation means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • GCP means the Good Clinical Practices officially published by EMA, FDA and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) that may be in effect from time to time and are applicable to the testing of the Compounds.

  • medicinal product means any substance or combination of substances presented for treating or preventing disease in human beings or animals and any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans or in animals;

  • CFDA means the Code of Federal Domestic Assistance assigned to a federal grant.

  • MFDA means the Mutual Fund Dealers Association of Canada;

  • ug/l means micrograms per liter.

  • Marketing Plan has the meaning set forth in Section 4.3(a).

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or Condition and is described in any of the following:

  • Global Development Plan has the meaning set forth in Section 3.1.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Licensed clinical social worker means an individual who meets the licensed clinical social worker requirements established in KRS 335.100.

  • Marketing program means a program established by order of the director pursuant to this act prescribing rules and regulations governing the marketing for processing, distributing, selling, or handling an agricultural commodity produced in this state or agricultural commodity input during a specified period and

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • spatial development framework means the Mhlontlo Municipal Spatial Development Framework prepared and adopted in terms of sections 20 and 21 of the Act and Chapter 2 of this By-Law;

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.